<DOC>
	<DOCNO>NCT01225419</DOCNO>
	<brief_summary>This prospective Phase II , monocentre study .</brief_summary>
	<brief_title>Mobilization Plerixafor Haematopoietic Stem Cells Children</brief_title>
	<detailed_description>The extensive chemotherapy follow hematopoietic stem cell reinjection ( HSC ) one therapeutic option profit well demonstrated treatment child 's solid tumor . It 's one `` standard '' treatment follow tumor : neuroblastoma , metastatic medulloblastoma , Ewing sarcoma , lymphoma relapse ; big chemosensibility paediatric cancer , stay important therapeutic option rhabdomyosarcoma relapse metastatic , nephroblastoma , etc . The stem cell take blood cytapheresis mobilization pharmacologic molecule . At present , reference mobilization treatment G-CSF ( Granulocyte colony-stimulating factor ) monotherapy 4 6 day . His inconvenience : last treatment ( 4 6 day ) , reproduction injection ( 1 2 subcutaneous injection daily ) , day variability peak mobilization , hematopoietic stimulation imposes delay chemotherapy . The plerixafor activates massive fast mobilization HSC ( hematopoietic stem cell ) ( 6 11 hour injection ) . Currently , 's indicated association G-CSF ( Granulocyte colony-stimulating factor ) case mobilization failure . However , big flexibility use could big interest monotherapy child . To date , knowledge data use molecule child . Schema study : Subcutaneous injection 240 µg/kg Plerixafor ( Mozobil ® , Genzyme ) 8 day cytapheresis . Determination CD34+ cell circulate h0 every hour h3 h11 . Taking cytapheresis 5th hour injection rate CD34+ upper equal 10.106/l . If rate CD34+ blood reach 10.106/l first injection plerixafor first cytapheresis allow collection least 5.106/kg CD34+ cell , patient consider failure conventional mobilization G-CSF ( Granulocyte colony-stimulating factor ) program .</detailed_description>
	<mesh_term>JM 3100</mesh_term>
	<criteria>0 18 year old Solid malign tumor Lansky score ≥ 70 % Indication hematopoietic stem cell take cytapheresis extensive chemotherapy follow one several reinjections hematopoietic stem cell Administration hematopoietic growth factor 8 day precede injection Plerixafor . Contraindication cytapheresis extensive chemotherapy . Clinical biological state dissuade realization cytapheresis Chemotherapy 15 day precede injection plerixafor neutrophil &lt; 1500/mm3</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Plerixafor</keyword>
	<keyword>Hematopoietic Stem Cell Transplant mobilization</keyword>
	<keyword>child</keyword>
</DOC>